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 Identified best performing rapid diagnostic kits detecting COVID-19 antibodies 
 Used a characterized reference panel of specimens to evaluate serological kits  
 For IgM/IgG, Autobio, MultiG and Standard Q had a Sensitivity and Specificity ≥98% 
 For IgG, Boson, MultiG, Standard Q, ViviaDiag had Sensitivity and Specificity ≥98% 
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Serological testing is needed to better understand the epidemiology of the SARS-CoV-2 
virus. Rapid Diagnostic Tests (RDTs) have been developed to detect specific antibodies, 
IgM and IgG, to the virus. We evaluated the performance of 25 of these RDTs. 
Methods 
A serological reference panel of 50 positive and 100 negative plasma specimens was 
developed from SARS-CoV-2 PCR and antibody positive patients and pre-pandemic 
SARS-CoV-2-negative specimens collected in 2016. Test performance of the 25 RDTs 
was evaluated against this panel. 
Results:  
A total of 10 RDTs had a sensitivity ≥98% while 13 RDTs had a specificity ≥98% to 
anti-SARS-CoV-2 IgG antibodies. Four RDTs; Boson, MultiG, Standard Q and 
ViviaDiag had both  sensitivity and  specificity of ≥98% to anti-SARS-CoV-2 IgG 
antibodies. Only 3 RDTs had a sensitivity ≥98% while 10 RDTs had a specificity ≥98% 
to anti-SARS-CoV-2 IgM antibodies.  Three RDTs; Autobio, MultiG and Standard Q, 
had sensitivity and specificity of ≥98% to combined IgG/IgM. The RDTs that 
performed well also had perfect or almost perfect inter-reader agreement. 
Conclusions:  
This evaluation identified three RDTs with a sensitivity and specificity to IgM/IgG 
antibodies of ≥98% with the potential for widespread antibody testing in Uganda.  




Coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health 
Organization (WHO) on March 11, 2020. Globally as of September 1
st
, 2021, there have 
been nearly 218 million cases reported to WHO with over 4.5 million deaths while in 
Uganda 99,408 cases with over 3000 deaths have been recorded (WHO 2021). Since 
this evaluation, the number of new cases and deaths continued to rise. 
Standard laboratory confirmation of severe acute respiratory syndrome-2 (SARS-COV-
2) is based on the detection of unique viral sequences in nasopharyngeal samples by 
NAAT (WHO 2020b).  Although the priority intervention from a public health 
perspective is to identify those with acute infection and to quarantine them and their 
immediate contacts in order to control the spread of infection, it quickly became 
apparent that it is also important to identify convalescent cases through antibody testing 
in order to better understand the epidemiology of the virus and thereby to introduce 
effective control measures. Antibody testing has traditionally been conducted using 
enzyme-linked immunosorbent assays (ELISAs) or more recently with RDTs. ELISAs 
facilitate the testing of large numbers of specimens per run while RDTs are lateral-flow 
devices for individual specimens. RDTs typically give results in less than 30 minutes 
and are therefore ideal for use at the point-of-care (POC). During the early days of the 
pandemic, commercial ELISAs and RDTs were hard to come by and none were 
approved for use in Uganda. 
Most people infected with SARS-CoV-2 have an incubation period of 3 - 7 days before 
the appearance of symptoms. IgM seroconversion occurs within 10 – 14 days and IgG 
seroconversion within 12 – 14 days after symptom onset (Long et al. 2020; Lou et al. 
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2020; To et al. 2020; Zhao et al. 2020) and can be detected in less than 40% of infected 
people within one week of symptom onset and in 100% by day 15 (Batra et al. 2020; 
Zhao et al. 2020). Antibodies can take much longer to develop in those with sub-clinical 
or mild infection (WHO 2020b). The strength of the antibody response depends on a 
number of factors including age, nutritional status and disease severity amongst others 
(WHO 2020a). IgM antibodies start to disappear by week 5 and by week 7 are no longer 
detectable – IgG antibodies persist beyond week 7 (Xiao et al. 2020). It is not clear if 
antibodies confer immunity to re-infection though recurrence of COVID-19 illness 
appears to be very uncommon (CDC 2020a). 
As a result of global shortages of reagents for molecular testing, a number of groups 
(Lassaunière et al. 2020; Zhao et al. 2020) investigated the potential use of antibody tests, 
particularly those for IgM, either singly or in combination, to diagnose acute COVID-9 infection. 
However, a reliable diagnosis of infection by antibody testing is only possible in the recovery 
phase when the possibility of intervening has passed and consequently serological diagnosis is 
not recommended for informing clinical management or contact tracing(WHO 2020b). 
In Uganda as in many other countries, there is a sense of urgency to understand the 
epidemiology of the virus in order to implement effective control measures. This 
requires mass screening of the population for anti-SARS-CoV-2 antibodies to determine 
among other things; how many people have been infected with the virus and how this 
changes over time; the risk factors for infection such as age, ethnicity, domicile or 
underlying health issues; the proportion of infected people with mild or asymptomatic 
infection and how long antibodies can be detected in individuals who have been 
infected (CDC 2021). Many countries are now testing for SARS-CoV-2 antibodies at the 
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population level or in specific groups, such as health workers, close contacts of known cases, or 
within households (WHO 2020c). 
The tools to conduct mass serological screening including ELISA and RDT kits with 
emergency use approval slowly became available in mid-2020 and plans were made to 
evaluate their performance.  
Laboratory tests, including RDTs, that detect antibodies to SARS-CoV-2 in people need 
validation to determine their accuracy and reliability. Inaccurate RDT results would have serious 
consequences and would affect pandemic control efforts. In Uganda, all new diagnostic 
assays that are introduced into the market must undergo in-country laboratory validation 
at the Uganda Virus Research Institute (UVRI), which is a designated WHO and Africa 
CDC SARS-CoV-2 reference laboratory, before being recommended to the Ministry of 
Health for use in the country. Both CDC and WHO also advise that diagnostic and 
antibody tests should be validated in appropriate populations and settings before they 
are recommended (CDC 2020b; WHO 2017). 
For this evaluation, ELISAs and chemiluminescent microparticle immunoassays 
(CMIA) with one or more approvals under the US Food and Drug Administration 
(FDA), Emergency Use Authorization (EUA) or the WHO Emergency Use Listing 
(EUL) or with the European Conformité Européenne (CE) mark were procured 
(Supplementary files, Appendix A). For the rapid tests, local distributors provided 25 
serological RDTs for a cost-free evaluation at UVRI (Supplementary files, Appendix 
B). Nine distributors provided enough test kits for the evaluation of 150 samples while 
16 distributors provided test kits for less than 150 samples (73-125). 
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Materials and methods 
Serological Reference Panel 
At UVRI, the normal practice to validate new antibody test kits is to evaluate their 
performance on a reference panel of well-characterized plasma specimens. In mid-2020 
no commercial nor WHO reference panels were available and consequently UVRI 
developed its own reference panel. Presumptive anti-SARS-CoV-2 antibody-positive 
specimens were selected from available qRT-PCR-confirmed, symptomatic and 
asymptomatic SARS-CoV-2 cases - the number of days post symptom onset was 
reported for some of the symptomatic cases. Presumptive SARS-CoV-2 antibody-
negative specimens were selected from the UVRI repository of specimens collected 
during an HIV national serosurvey conducted in 2016, long before the COVID-19 
pandemic. 
Specimens from qRT-PCR-confirmed SARS-CoV-2-positive cases were tested on the 6 
assays below following the manufacturer’s Information for Use (IFU) instructions; 
Architect SARS-CoV-2 IgG CMIA (nucleocapsid protein) 
Architect SARS-CoV-2 IgM CMIA (spike protein) 
Euroimmun Anti-SARS-CoV-2 ELISA (IgG) (spike protein) 
EDI Novel Coronavirus COVID-19 IgG ELISA (nucleocapsid protein) 
EDI Novel Coronavirus COVID-19 IgM ELISA (nucleocapsid protein) 
InBios SCoV-2 Detect IgM ELISA (spike protein) 
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A positive sample was defined as a sample reactive on at least two IgG ELISA/CMIA 
targeting the spike protein (Euroimmun Anti-SARS CoV-2 ELISA-IgG) and the 
nucleocapsid protein (Architect SARS-CoV-2 IgG CMIA) and also reactive on at least 
two IgM ELISA/CMIA targeting the spike protein (InBios SCoV-2 Detect IgM ELISA 
and Architect SARS-CoV-2 IgM CMIA).  EDI Novel Coronavirus COVID-19 IgG and 
IgM ELISA had low sensitivity and hence results with these assays were not considered 
during selection of specimens for the positive panel. 
Fifty samples with the above profile were included in the SARS-CoV-2-positive 
reference panel (UVRI 2021). 
SARS-CoV-2-(presumed) negative specimens were tested on the 4 assays below 
following the manufacturer’s IFUs; 
InBios-SCoV-2 Detect IgM ELISA (spike protein) 
Euroimmun Anti-SARS CoV-2 ELISA- IgG (spike protein) 
Architect SARS CoV2-IgG CMIA (nucleocapsid protein) 
SD Biosensor Standard E COVID-19 Total Ab ELISA (spike protein) 
A negative sample was defined as a sample, non-reactive on at least three of the four 
assays.  
One hundred samples with the above profile were included in the SARS-CoV-2-
negative reference panel (UVRI 2021). 
Rapid Diagnostic Tests 
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A total of 25 serological RDTs (Appendix B) were evaluated against the characterized 
serological reference panel. The antigen(s), spike and/or nucleocapsid protein, targeted 
by the RDTs was not disclosed in the IFUs for most of the RDTs. The majority of RDTs 
had a single reading window with a control line, an IgM test line and an IgG test line 
while one (Biocredit) had two separate cassettes. Two RDTs had a reading window for 
IgM/IgG (Sino Care and Wondfo), while one had reading windows for IgG and 
IgA/IgM and not IgM (Antai). The manufacturer’s IFUs were followed, and results read 
by 2 technicians blinded to each-others results.  
Statistical Analysis 
The statistician conducting the data analysis was blinded to the RDT identity. Only 
concordant results between technicians were used to evaluate the performance of the 
RDTs – inter-reader variability was also documented. 
Sensitivity 
The sensitivity was calculated as the number of specimens determined as positive by the two 
technicians for each RDT under evaluation divided by the number of specimens tested from the 
positive panel and expressed as a percentage.  
Specificity 
The specificity was calculated as the number of specimens determined as negative by the two 
technicians for each RDT under evaluation divided by the number of specimens tested from the 
negative panel and expressed as a percentage. 
Accuracy 
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The accuracy was calculated as the proportion of RDT test results that agreed with the panel 
source (positive and negative panels) and expressed as a percentage. The sensitivity, specificity, 
and accuracy calculations were performed using the proportion command in STATA 15 and 
confidence intervals produced with the Wilson score method (Newcombe 1998).   
Sensitivity, specificity, and accuracy were also determined for combined IgM/IgG (either or both 
IgM and IgG). 
Inter-reader agreement 
The observed proportion and level of agreement between the two technicians were 
generated using the Cohen’s Kappa statistic. This was generated for each isotype (IgM 
and IgG) of each RDT evaluated. The level of agreement was categorized as No 
agreement (<0), Slight agreement (0.0-0.20), fair agreement (0.21-0.40), moderate 
agreement (0.41-0.60), substantial agreement (0.61-0.80) and almost perfect agreement 
(0.81-1.00) (McHugh 2012). 
Ethical considerations 
The evaluation protocol was reviewed and approved by UVRI’s Research Ethics Committee and 
the Uganda National Council for Science and Technology (UNCST). The panels were unlinked 
to personal identifiers and results could not be traced to individual patients. Consent to 
participate and to store samples for future use was also sought. 
Results 
Performance 
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Results by individual RDT performance are summarized (in alphabetical order) in Table 
1. Most RDTs showed poor performance with none showing both anti-SARS-CoV-2 
IgM and IgG antibody sensitivity and specificity ≥98%. Many RDTs that performed 
well in at least one reading window showed good reactivity to anti-SARS-CoV-2 IgG 
antibodies with 10 having a sensitivity ≥98% while 13 had a specificity ≥98% (Table 1). 
Only three RDTs had an anti-SARS-CoV-2 IgM antibody sensitivity ≥98% while ten 
RDTs had a specificity ≥98% for anti-SARS-CoV-2 IgM antibodies. Three RDTs; 
Autobio, MutltiG and Standard Q had a sensitivity and a specificity ≥98% to combined 
IgM/IgG. There were seven RDTs that had an accuracy ≥98% for anti-SARS-CoV-2 
IgG antibodies with three (Boson, Standard Q and ViviaDiag) having an accuracy of 
100%. There were four RDTs (Boson, MultiG, Standard Q, ViviaDiag) where both anti-
SARS-CoV-2 IgG antibody sensitivities and specificities were ≥98%. 
Inter-reader agreement 
There was almost perfect agreement between the two technicians for determination of 
IgG in 20/23 (87.0%) RDTs (where there was a reading window for IgG). Four of the 
RDTs had perfect agreement for IgG with Kappa statistic of 100% (Biocredit, BTNX, 
MultiG, Standard Q, ViviaDiag).  Agreement in determining IgM was much lower with 
only 11/23 (47.8%) tests where there was almost perfect agreement (Table 2). 
Discussion 
The WHO continues to review the evidence on antibody responses to SARS-CoV-2 infection 
and has published guidance on adjusting public health and social measures for the next phase of 
the COVID-19 response (WHO 2019). The development of accurate RDTs for the diagnosis of 
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anti-SARS-CoV-2 IgM and IgG antibodies will benefit epidemiological and surveillance studies 
in identifying past COVID-19 symptomatic and asymptomatic infections including those in ‘hot-
spots’. This will serve as an aid in determining the extent of herd immunity, though for how long 
immunity will last, especially with the appearance of SARS-CoV-2 variants is not yet known 
(Aschwanden 2021).  Accurate RDTs detecting the relevant antibodies, will benefit vaccine 
studies in identifying SARS-CoV-2 vaccine responders and for how long one remains immune to 
the virus.  
This evaluation of 25 RDTs showed significant variation in performance emphasizing the need 
for more input in research and development in order to come up with more accurate tests. There 
were only four RDTs that had a sensitivity and specificity ≥98% for anti-SARS-CoV-2 
IgG i.e. Boson, MultiG, Standard Q and ViviaDiag. Of these four RDTs, only Boson 
had a sensitivity ≥98% for anti-SARS-CoV-2 IgM (sensitivity was 100% and 
corresponding specificity was 87.0 for anti-SARS-CoV-2 IgM; Table 1) When one 
combines IgM and IgG, our evaluation identified three RDTs; Autobio, MultiG and 
Standard Q with a sensitivity and specificity ≥98% for both IgG and/or IgM. 
There was better agreement between the two technicians for result determination of IgG 
compared to result determination of IgM with 87% having almost perfect agreement for 
IgG compared to only 47.8% for IgM. Four of the RDTs had perfect agreement for IgG 
with Kappa statistic of 100% (Biocredit, BTNX, MultiG, Standard Q, ViviaDiag) while 
there was no such finding for IgM. 
Combination IgG/IgM RDTs can provide unclear results given the potential for cross-
reactivity of antibodies with other coronavirus and the often poor specificity of IgM 
serological assays (IDSA 2020). Use of some of these combination IgG/IgM RDTs may 
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not be simple to interpret in the field if only the IgG test component of the RDT gives 
accurate results. Some RDTs had one cassette with separate IgM and IgG bands, others 
have separate cassettes for IgG and IgM. If one used an RDT with a cassette having 
both IgM and IgG and with IgM having poor specificity then the final result describing 
past exposure may be confusing and inaccurate, unless the reader disregards the IgM 
results altogether.  
For the above reasons, it may be more practical to recommend the use of RDTs with 
both a sensitivity and specificity of ≥98% for IgM and IgG combined - Autobio, MultiG 
and Standard Q fit this profile.  
All the test kits we recommend above for IgG (Boston, Multi G, Standard Q, and 
ViviaDiag) had almost perfect agreement, similarly for either IgG or IgM (IgG/IgM) 
MultiG and Standard Q, had almost perfect agreement while Autobio had substantial 
agreement. 
To evaluate the performance of the 25 RDTs we used a well-characterized, reference 
panel of plasma specimens from SARS-CoV-2 qRT-PCR-positive individuals that had 
been screened on 6 SARS-CoV-2 ELISA/CMIA IgM and IgG assays. This approach is 
different from many other studies that have used any samples from qRT-PCR-positive 
individuals. The reason for this approach is that not all qRT-PCR-positive individuals 
have antibodies; the presence of antibodies depends on the time since infection, the 
severity of infection and a number of other factors. A further step to increase the 
relevance of reference panel was to include ELISA/CMIA kits that targeted either the 
nucleocapsid or the spike antigen where possible. 
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There are other published evaluation reports that have similarly shown poor serological 
RDT performance compared to that reported by the manufacturer (Deeks et al. 2020; 
Jacobs et al. 2020; Vauloup-Fellous et al. 2021). Since some of these other studies used 
samples from any qRT-PCR positive individuals, they show lower sensitivity in the first 
week post symptom onset with improved performance at later time points. Few studies 
have evaluated RDTs using samples taken beyond a month post symptom onset. 
Furthermore, there is limited information on the performance of these RDTs in 
asymptomatic participants (Deeks et al. 2020). 
While a serial or orthogonal (Xu et al. 2020) testing approach has been recommended 
for surveillance especially when using ELISAs (CDC 2020b), here we propose that 
parallel testing with RDTs could also be a viable approach. With that approach, two 
RDTs with ≥ 98% sensitivity and specificity could be used together with an equally 
accurate RDT as a tie-breaker for discrepant results.   
Our study evaluated only 25 RDTs but we are aware that many SARS-CoV-2 RDT kits 
are on market. With the well characterized panel of samples we now have and with 
WHO serological reference standards now available from the National Institute for 
Biological Standards and Control (NIBSC), validation of additional RDTs will be 
quicker. 
The study had some limitations. The selection of the RDTs to evaluate was dictated by 
what was availed to us by the local distributors in the country. Some distributors 
provided test kits for evaluation, less than the desired 150 samples. Another limitation 
was that we were not able to procure an IgM ELISA based on the nucleocapsid protein. 
Some of the ELlSA kits we procured did not perform well and hence results with these 
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kits were excluded from the development of the serological reference panel. Subsequent 
to the completion of this evaluation, it was discovered that authorization for the use of some of 
the RDTs had been revoked and removed from the FDA EUA notification list as of 23.2.21. 
Conclusion 
Using a reference panel of well characterized plasma samples and considering the 
sensitivity and specificity of combined IgG and IgM results, and inter-reader 
agreements, our evaluation found that three RDTs, Autobio, MultiG and Standard Q 
performed well. Where only the IgG result is of interest, there were four RDTs; Boson, 
MultiG, Standard Q, and ViviaDiag that performed well. 
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Table 1: Field performance (sensitivity, specificity and accuracy) of 25 Rapid 





































































































































































































































































































































































































































































IgM NA* NA NA 














































































































































IgM NA NA NA 

































NA: The sensitivity and specificity of these tests cannot be generated separately because 
the kits did not have separate reading windows for IgM and IgG  
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Table 2: The observed proportion of agreement and Cohen’s Kappa statistic for the 25 RDTs  
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